HIV Medications for HIV Prevention
Basics
- PrEP (Pre-Exposure Prophylaxis) (June 2, 2009)
Complex questions surround biomedical option for preventing HIV infection.
From Project Inform
- Q&A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention: Anticipated Results and Impact (January 26, 2009)
From U.S. Centers for Disease Control and Prevention
- Q&A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention: Community Involvement in These Studies (January 26, 2009)
From U.S. Centers for Disease Control and Prevention
- Q&A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention: Research Rationale (January 26, 2009)
From U.S. Centers for Disease Control and Prevention
- Q&A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention: Safeguards and Services for Trial Participants (January 26, 2009)
From U.S. Centers for Disease Control and Prevention
- Q&A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention: Trial Designs and Objectives (January 26, 2009)
From U.S. Centers for Disease Control and Prevention
- Antiretroviral Therapy as Pre-Exposure Prophylaxis: A Continuous Vaccine? (Winter 2007/2008)
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
- Before and After: PrEP and PEP (Summer 2007)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
- Q & A: CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention (April 2007)
To read PDF, click here
From U.S. Centers for Disease Control and Prevention
News & Research
- Clinical Trial of Antiretroviral-Based HIV Prevention Strategies for Women Now Under Way (September 16, 2009)
From U.S. National Institute of Allergy and Infectious Diseases
- Questions and Answers: The VOICE HIV Prevention Study (September 16, 2009)
From U.S. National Institute of Allergy and Infectious Diseases
- Prepping for a PrEP Trial (July/August 2009)
Why is it so hard to find young people to participate in HIV-related studies? While trying to find an assistant to help recruit young, gay men for a trial of pre-exposure HIV prophylaxis (PrEP), HIV advocate Keith Green may have stumbled on an answer: homophobia.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Low Bone Mineral Density in Botswana PrEP Trial Participants Raises Concerns (July 24, 2009)
Researchers conducting a trial of tenofovir and emtricitabine as pre-exposure prophylaxis (PrEP) in Botswana have found low bone mineral density levels in HIV-uninfected volunteers at enrollment.
From aidsmap.com
- Antiretrovirals Can Be Used to Prevent Spread of HIV/AIDS, Model Shows (July 21, 2009)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- The Promise of Pre-Exposure Prophylaxis (June 1, 2009)
To read PDF, click here
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Herpes Drug Acyclovir Does Not Reduce Risk of HIV Transmission, Does Slow HIV Progression, Study Says (May 14, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Could Isentress (or Other Integrase Inhibitors) Be Used as an HIV Prevention Drug? (April 28, 2009)
From aidsmap.com
- Inter Press Service Examines Research Into PrEP (April 6, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Pre-Exposure Prophylaxis (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- HIV Pre-Exposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes and Cost-Effectiveness (February 26, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Intermittent Oral PrEP May Be as Effective as Daily Oral PrEP for Prevention of Rectal HIV Transmission, Macaque Study Suggests (February 9, 2009)
Gerardo Garcia-Lerma, Ph.D., presents data from a macaque study utilizing a unique method of pre-exposure prophylaxis: oral tenofovir/emtricitabine administered just once prior to exposure, followed by a second dose shortly after exposure.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- ABC News Examines Pre-Exposure Prophylaxis for HIV Prevention (January 22, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- For Post-Exposure HIV Prevention, Viread May Be Gentler Option than Retrovir (April 17, 2008)
From Reuters Health
- New Frontiers in HIV Prevention: Male Circumcision and Pre-Exposure Prophylaxis in the United States -- An Interview at CROI 2007 With Patrick Sullivan, Ph.D., and Lynn Paxton, M.D., M.P.H. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- HIV Clinical Trial Aiming to Increase Participation of Black MSM (January 11, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Antiretroviral Drugs as Prevention Tools: PEP, PrEP and Prevention for Positives (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- PrEP Studies Show Possible Effectiveness; Scientists Say Further Tests Must Be Completed for Confirmation (August 14, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Can a Pill a Day Keep HIV Away? Educators Warn Against Jumping the Gun (May 5, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
|
|
Advertisement
|
E-Mail
Glossary
Share
